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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
phaseolamine and reduction in body weight (ID 1701) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to phaseolamine and reduction in body weight. The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claim is phaseolamine. The Panel considers that 
phaseolamine is sufficiently characterised in relation to the claimed effect.  
The claimed effect is “inhibit α-amylase activity, hindering the conversion of complex carbohydrate 
to simple sugars, which are stored as reservoir fats if not immediately utilised by the organism; it 
results in a lower calories intake, contributing to weight loss”. The target population is assumed to be 
overweight individuals in the general population who wish to reduce their body weight. In the context 
of the proposed wordings, the Panel assumes that the claimed effect refers to a reduction in body 
weight. The Panel considers that reduction in body weight is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that although one short-term (30 day) 
intervention study in humans showed an effect of phaseolamine consumption on reduction in body 
weight, a second human intervention study, using higher phaseolamine doses and of longer duration 
(eight weeks), did not show an effect of phaseolamine consumption on body weight changes at any 
time point considered.  
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-2437, adopted on 25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
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Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. 
 
Phaseolamine and reduction in body weight 
 
2 EFSA Journal 201;9(6):2253 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of phaseolamine and reduction in body weight.  
KEY WORDS 
Phaseolamine, body weight, health claims.  
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 1701) 
The food constituent that is the subject of the health claim is phaseolamine.  
Phaseolamine is a generic name for a proteinaceous inhibitor of animal alpha-amylases that is 
obtained from kidney beans (Phaseolus vulgaris L.) and which can be purified to homogeneity by 
conventional protein fractionation methods (Marshall and Lauda, 1975). Different extracts 
standardised by their in vitro alpha-amylase inhibitory activity exist on the market.  
The Panel considers that the food constituent, phaseolamine, which is the subject of the health claim, 
is sufficiently characterised in relation to the claimed effect.  
2. Relevance of the claimed effect to human health (ID 1701) 
The claimed effect is “inhibit α-amylase activity, hindering the conversion of complex carbohydrate 
to simple sugars, which are stored as reservoir fats if not immediately utilised by the organism; it 
results in a lower calories intake, contributing to weight loss”. The Panel assumes that the target 
population is overweight individuals in the general population who wish to reduce their body weight. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to reduction 
in body weight.  
Weight loss can be interpreted as the achievement of a normal body weight in previously overweight 
subjects. In this context, weight loss in overweight subjects without the achievement of a normal body 
weight is considered to be a beneficial physiological effect. 
The Panel considers that reduction in body weight is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 1701) 
The references provided for the scientific substantiation of the claim included human studies which 
reported on health outcomes unrelated to the claimed effect (e.g post-prandial blood glucose 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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responses), and a study on the extraction process and purification of phaseolamine. The Panel 
considers that no conclusions can be drawn from these references for the scientific substantiation of 
the claim. 
An open label, one arm human intervention study which investigated the effects of consuming a food 
supplement containing 750 mg phaseolamine per capsule (three capsules twice daily) for eight weeks 
on body weight in 10 overweight subjects was provided (Koike et al., 2005). The Panel considers that 
no conclusions can be drawn from this uncontrolled study for the scientific substantiation of the 
claim.  
In a randomised, placebo-controlled, human intervention study (Udani et al., 2004), 39 obese subjects 
(4 males, age range 20-69 years) were randomly allocated to consume 1,500 mg of a water extract 
from Phaseolus vulgaris L. (phaseolamine, n=20) or placebo (n=19) twice daily at lunch or dinner for 
eight weeks in the context of a “low-fat/high fibre” diet providing 100-200 g of complex 
carbohydrates mainly at the main meals. A total of 27 subjects completed the study. Data analysis was 
intention-to-treat. Body weight was assessed at weeks 2, 4, 6 and 8 of the study. No significant 
differences in body weight changes between groups were observed during the study at any time point. 
The Panel notes that consumption of phaseolamine did not lead to a significant reduction in body 
weight compared to placebo in this study.  
In a second randomised, placebo-controlled, human intervention study (Celleno et al., 2007), 
60 overweight subjects were randomly allocated to consume an 800 mg tablet containing 445 mg of a 
dried water extract from Phaseolus vulgaris L. (phaseolamine) standardised to a minimum of 
3,000 alpha-amylase inhibiting units (n=30) or placebo (microcrystalline cellulose and maltodextrin, 
n=30) once daily before the main, carbohydrate-rich, meal for 30 days, after a two-week run-in phase 
in which all subjects received placebo. Dietary recommendations were provided to all subjects, and 
these recommendations included a daily intake of complex carbohydrates concentrated in one or two 
meals. The study diet provided 2000-2200 kcal/day. A total of 59 subjects (29 controls) completed the 
study and entered data analysis. A significant reduction in body weight was observed in the 
intervention group (-2.93 1.16 kg) compared to placebo (-0.35 0.38 kg, p<0.001). The Panel notes 
the short duration of the study. 
In vitro studies which investigated the effects of phaseolamine on amylase activity and starch 
digestion were also provided. The Panel considers that evidence provided in in vitro studies is not 
sufficient to predict an effect of phaesolamine on starch ingestion in vivo in humans. 
In weighing the evidence, the Panel took into account that although one short-term (30 day) 
intervention study in humans showed an effect of phaseolamine consumption on reduction in body 
weight, a second human intervention study using higher phaseolamine doses and of longer duration 
(eight weeks), did not show an effect of phaseolamine consumption on body weight changes at any 
time point considered.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of phaseolamine and reduction in body weight.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, phaseolamine, which is the subject of the health claim, is sufficiently 
characterised in relation to the claimed effect. 
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 The claimed effect is “inhibit α-amylase activity, hindering the conversion of complex 
carbohydrate to simple sugars, which are stored as reservoir fats if not immediately utilized 
by the organism; it results in a lower calories intake, contributing to weight loss”. The target 
population is assumed to be overweight individuals in the general population who wish to 
reduce their body weight. Reduction in body weight is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
phaseolamine and reduction in body weight. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2437). 
The scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
Phaseolamine and reduction in body weight 
 
9 EFSA Journal 201;9(6):2253 
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Phaseolamine and reduction in body weight 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
Phaseolamine and reduction in body weight 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
Phaseolamine and reduction in body weight 
 
12 EFSA Journal 201;9(6):2253 
APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to phaseolamine, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
ID 
Food or Food 
constituent 
Health Relationship Proposed wording 
1701 Phaseolamine (proteina 
concentrata di fagiolo 
Phaseolus vulgaris). 
Clarification provided 
Phaseolamine (bean's 
protein concentrated -
Phaseolus vulgaris). 
Inibisce l’attività dell’enzima α-
amilasi, ostacolando in tal modo la 
trasformazione dei carboidrati 
complessi in zuccheri semplici, i 
quali vengono immagazzinati come 
grassi di deposito se non utilizzati 
subito dall’organismo. Ne risulta una 
diminuzione delle calorie assorbite 
con conseguente perdita di peso. 
Clarification provided 
Inhibit α-amylase activity, hindering 
the conversion of complex 
carbohydrate to simple sugars, which 
are stored as reservoir fats if not 
immediately utilized by the organism. 
It result in a lower calories intake, 
contributing to weight loss. 
Con proteina concentrata di 
fagiolo che AIUTA A 
DIMAGRIRE. 
Clarification provided 
With concentrated bean 
proteins, which contributes to 
weight reduction. 
Conditions of use 
- Aggiunta ad un mix a base di farina per pane. 
 
